Avacta/Daewoong’s Joint-Venture AffyXell Paves Way For Next-Generation Stem Cell Therapy
Novel Mesenchymal Stem Cells To Secrete Antibody Mimetic Affimers
Executive Summary
A new joint venture from Avacta and Daewoong Pharmaceutical aims to use novel mesenchymal stem cells to secrete antibody mimetic "Affimers" to treat inflammatory diseases.
You may also be interested in...
Asia Deal Watch: Genexine Teams With KGBio In Immuno-Oncology, COVID-19 Therapy
Plus deals involving Scynexis/Hansoh, Cend/Qilu, Apollomics/Edison, Apollomics/Iterion, Apollomics/Nuance, Aerami/Chance, Antibe/Nuance, Ildong/Arbormed
Deal Watch: BMS Looks To Molecular Templates’ Engineered Toxin Bodies In Cancer
Plus recent deals involving AbbVie/Caribou, Sanofi/i2O, Merck & Co./Starpharma, Protalix/SarcoMed, Targovax/Papyrus, Medivir/Ubiquigent, Eton/Azurity
Execs On The Move, February 2021
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Need a specific report? 1000+ reports available
Buy Reports